UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2019 » Volume 27, issue 2 (99) » Problem of interrelations of effi cacy and safety during pharmacotherapy in angioneurology: focus on ginkgo preparations

Problem of interrelations of effi cacy and safety during pharmacotherapy in angioneurology: focus on ginkgo preparations

Authors

Type of Article

  • Scientific Article

In the Section

  • TO HELP A PRACTICING PHYSICIAN

Key words

Index UDK:
  • 616.8-005-08 : 615.272

Abstract

In the present article a modern criteria defi ned the terms "effi cacy" and "safety" during pharmacotherapy in cerebrovascular pathology have been looked. A main risks and possible adverse eff ects of widely used nootropic and vasotropic drugs in angioneurologic practice have been analyzed. Advantages of use the neurotropic phytodrugs and especially preparations of Ginkgo biloba have been looked in details. Use as an optimal instrument of pharmacotherapy in cerebrovascular pathology the drug Bilobil-Intens has been grounded based on the point of view of its complex clinical-pharmacological eff ect and safety criteria.

Pages

  • 73-77

Year / Issue

Download PDF

References

  1. Avedisova AS, Akhapkin R. V., Akhapkina V. I., Verigo NI. V., Akhapkina V. I., Verigo N. I. Analysis of foreign studies of nootropic drugs (on the example of piracetam) // Russian Psychiatric Journal. 2001. № 1. С. 46-53.
  2. Burchinsky S.G. Nootropics: classification, mechanisms of action, comparative characterization of pharmacological properties. Kiev, 2004. 21 с.
  3. Burchinsky S. G. Dangers and risks of nootropic pharmacotherapy: myth or reality? // Rational Pharmacotherapy. 2007. № 1. С. 62-66.
  4. Zakharov V. V., Bakulin I. S. Bilobil Intens - neuroprotective drug of plant origin: spectrum of application in neurology // Nervous Diseases. 2017. № 1. С. 15-20.
  5. Kamchatnov P. R., Chugunov A. V., Umarova H. Ya. V., Umarova H. Y. Vertebral-basilar insufficiency - issues of diagnosis and treatment // Consilium Medicum. 2005. Т. 7, № 2. С. 142-146.
  6. Kamchatnov P. R. Opportunities for the use of Ginkgo biloba extract (memoplant) in neurological practice // Journal of Neurology and Psychiatry named after S. S. Korsakov. 2010. Т. 110, № 5. С. 51-56.
  7. Kuznetsova S. M., Shulzhenko D. V. Ginkgo biloba extract in the strategy of treatment of chronic vascular diseases of the brain // International Neurological Journal. 2014. № 1 (63). С. 109-115.
  8. Mishchenko TS, Mishchenko VN, Lapshina IA Bilobil Intens in the treatment of patients with dyscirculatory encephalopathy complicated by atherosclerosis and arterial hypertension // Ibid. 2012. № 6. С. 9-14.
  9. Mishchenko T. S. Epidemiology of cerebrovascular diseases and organization of care for patients with cerebral stroke in Ukraine // Ukrainian Vysnik Psychoneurology. 2017. Т. 25, vip. 1 (90). С. 22-24.
  10. Moskovko S.M. Nootropic choice: considerations of the syndromic and symptomatic approach // International Neurological Journal. 2012. № 6. С. 95-98. URL: http://nbuv.gov.ua/UJRN/Mnzh_2012_6_15.
  11. Shahparonova NV, Kadykov AS Place of the drug Bilobil in the complex therapy of vascular diseases of the brain // Liki Ukrainy. 2010. № 9. С. 54-56.
  12. Shtrygol S. Yu, Kortunova T. V., Shtrygol D. V. Side effects of nootropic drugs // Provisor. 2003. № 11. URL: http://www.provisor.com.ua/archive/2003/N11/art_31.php.
  13. Elgood A. L. Use of nootropic drugs in general practice: meta-analysis // J. Clin. Pract. Pharm. 2012. Vol. 9. P. 114—123.
  14. Ihl R. Gingko biloba extract EGb 761: clinical data in dementia // Int. Psychogeriatr. 2012. Vol. 24, suppl. 1. P. S35—S40. DOI: https://doi.org/1017/S1041610212000543.
  15. Kaschel B. Ginkgo biloba: specificity of neuropsychological improvement — a selective review in search of differential effects // Hum. Psychopharmacol. 2009. Vol. 24. P. 343—370. DOI: https://doi.org/1002/hup.1037.
  16. Koch E. Inhibition of platelet activating factor (PAF)- induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts // Phytomedicine. 2005. Vol. 12. P. 10—16. DOI: https://doi.org/10.1016/j.phymed.2004.02.002.
  17. Lender P. Pharmacotherapy of epilepsy: safety problems // Epilepsia. Modern Aspects of Treatment. Chicago : Illinois Univ Ed., 2010. P. 184—199.
  18. Marti-Masso J. F., Poza J. J. Cinnarizine-induced parkinsonism : ten years later // Mov. Disord. 1998. Vol. 13. P. 453—456.
  19. Morgenstern C., Biermann E. The efficacy of Gingko biloba special extract EGb 761 in patients with tinnitus // J. Clin. Pharmacol. Ther. 2002. Vol. 40. P. 188—197. PMID: 12051570.
  20. Paljk M., Vitezič P., Milharčič Simčič M. Bilobil — clinically confirmed effective and safe Ginkgo biloba medicine satisfying the highest quality standards // Krka Med Farm. 2014; 26 (38): 144—154.
  21. Schatzberg A. F., Nemeroff C. B. Textbook of Psychopharmaco logy. Washington : Amer. Psychiatr. Ass., 2007. 824 p.
  22. Sollier C. B. D., Caplain H., Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study // Clin. Lab. Haematol. 2003. Vol. 25(4). P. 251—253. PMID: 12890165.
  23. Stefanache F. The monitoring of the efficiency and safety of Bilobil Intens treatment in patients with moderate and severe cognitive impairment and peripheral blood flow impairment // Rom. J. Neurol. 2011. Vol. 10 (3). P. 154—157.
  24. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and metaanalysis / Tan M. S., Yu J. T., Tan C. C. [et al.] // J. Alzheimer’s Dis. 2015. Vol. 43. P. 589—603. DOI: https://doi.org/10.3233/JAD-140837.
  25. Underwood P. K., Lindsey R. Long-term pharmacotherapy in cardiology and cardiovascular risk: how it can be reduced ? // Ann. Cardiovasc. Pharmacol. 2011. Vol. 6. P. 44—60.
  26. WHO information. Calcium channel blockers and Parkinson’s disease // Drug Inform. 2002. Vol. 23, № 4. P. 27—29.
  27. Winblad B. Piracetam: a review of pharmacological properties and clinical use // CNS Drug Rev. 2005. Vol. 11. P. 169—182. PMID: 16007238.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»